LEXICON PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $49.8M | $31.1M | $1.2M | $139,000 | $298,000 |
| Operating income | -$48.9M | -$197.1M | -$171.8M | -$100.8M | -$87.1M |
| Operating expenses | — | — | — | $100.9M | $87.4M |
| Cost of revenue | $274,000 | $616,000 | $85,000 | $0 | $0 |
| Cash from operations | -$67.9M | -$178.8M | -$161.9M | -$88.9M | -$87.0M |
| Capital expenditure | $0 | $1.0M | $470,000 | $1.3M | $1.2M |
| Free cash flow | -$67.9M | -$179.8M | -$162.4M | -$90.2M | -$88.2M |
| Share repurchases | — | $1.7M | $824,000 | $864,000 | $2.7M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $185.0M | $298.4M | $229.4M | $194.3M | $136.9M |
| Total liabilities | $77.4M | $152.5M | $136.3M | $77.2M | $23.3M |
| Total debt | — | — | — | $48.6M | — |
Shares outstanding 444.2M · Free float 46.2%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.